Journal of Hepatology
Volume 56, Supplement 1 , Pages S25-S38, 2012

Management of hepatic vascular diseases

  • Aurélie Plessier

      Affiliations

    • Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3
  • ,
  • Pierre-Emmanuel Rautou

      Affiliations

    • Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3
  • ,
  • Dominique-Charles Valla

      Affiliations

    • Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3
    • Université Paris 7-Denis-Diderot, Clichy, UFR de Médecine, Paris 75018, France
    • Corresponding Author InformationCorresponding author. Address: Service d'Hépatologie and INSERM CRB3, Hôpital Beaujon, AP-HP, Clichy, France. Tel.: +33 1 40 87 55 94; fax: +33 1 40 87 44 26

Summary 

Primary damage to hepatic vessels is rare. (i) Hepatic arterial disorders, related mostly to iatrogenic injury and occasionally to systemic diseases, lead to ischemic cholangiopathy. (ii) Hepatic vein or inferior vena cava thrombosis, causing primary Budd-Chiari syndrome, is related typically to a combination of underlying prothrombotic conditions, particularly myeloproliferative neoplasms, factor V Leiden, and oral contraceptive use. The outcome of Budd-Chiari syndrome has markedly improved with anticoagulation therapy and, when needed, angioplasty, stenting, TIPS, or liver transplantation. (iii) Extrahepatic portal vein thrombosis is related to local causes (advanced cirrhosis, surgery, malignant or inflammatory conditions), or general prothrombotic conditions (mostly myeloproliferative neoplasms or factor II gene mutation), often in combination. Anticoagulation at the early stage prevents thrombus extension and, in 40% of the cases, allows for recanalization. At the late stage, gastrointestinal bleeding related to portal hypertension can be prevented in the same way as in cirrhosis. (iv) Sinusoidal obstruction syndrome (or venoocclusive disease), caused by agents toxic to bone marrow progenitors and to sinusoidal endothelial cells, induces portal hypertension and liver dysfunction. Decreasing the intensity of myeloablative regimens reduces the incidence of sinusoidal toxicity. (v) Obstruction of intrahepatic portal veins (obliterative portal venopathy) can be associated with autoimmune diseases, prothrombotic conditions, or HIV infection. The disease can eventually be complicated with end-stage liver disease. Extrahepatic portal vein obstruction is common. Anticoagulation should be considered. (vi) Nodular regenerative hyperplasia is induced by the uneven perfusion due to obstructed sinusoids, or portal or hepatic venules. It causes pure portal hypertension.

Keywords:  Portal hypertension , Hepatic venous outflow , Portal vein thrombosis , Cavernoma , Ischemic cholangiopathy , TIPS , Liver transplantation , Angioplasty , Anticoagulation , Idiopathic portal hypertension

Abbreviations:  HIV, human immunodeficiency virus , CT, computed tomography , BCS, Budd-Chiari syndrome , SOS, Sinusoidal obstruction syndrome , VOD, venoocclusive disease , OPV, obliterative portal venopathy , NRH, nodular regenerative hyperplasia , NCIPH, Non cirrhotic intrahepatic portal hypertension , IPH, Idiopathic portal hypertension

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(12)60004-X

doi:10.1016/S0168-8278(12)60004-X

Journal of Hepatology
Volume 56, Supplement 1 , Pages S25-S38, 2012